[go: up one dir, main page]

ES2097816T3 - Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes. - Google Patents

Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.

Info

Publication number
ES2097816T3
ES2097816T3 ES91915377T ES91915377T ES2097816T3 ES 2097816 T3 ES2097816 T3 ES 2097816T3 ES 91915377 T ES91915377 T ES 91915377T ES 91915377 T ES91915377 T ES 91915377T ES 2097816 T3 ES2097816 T3 ES 2097816T3
Authority
ES
Spain
Prior art keywords
hypocaloric
amounts
treatment
ifg
nutrients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91915377T
Other languages
English (en)
Other versions
ES2097816T5 (es
Inventor
Linda Fryklund
Peter Gluckman
Anna Skottner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097816(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2097816T3 publication Critical patent/ES2097816T3/es
Publication of ES2097816T5 publication Critical patent/ES2097816T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE PRESENTA UN METODO Y UN PRODUCTO PARA EL TRATAMIENTO O PREVENCION DE ESTADOS CATABOLICOS EN UN PACIENTE EN EL QUE EL PACIENTE SE TRATA CON IGF-1 Y UNA CANTIDAD HIPOCALORICA DE NUTRIENTES, DE FORMA, POR EJEMPLO INTRAVENOSA.
ES91915377T 1990-08-24 1991-08-22 Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes. Expired - Lifetime ES2097816T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9002731A SE9002731D0 (sv) 1990-08-24 1990-08-24 Product comprising growth factor

Publications (2)

Publication Number Publication Date
ES2097816T3 true ES2097816T3 (es) 1997-04-16
ES2097816T5 ES2097816T5 (es) 2003-07-16

Family

ID=20380208

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91915377T Expired - Lifetime ES2097816T5 (es) 1990-08-24 1991-08-22 Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.

Country Status (14)

Country Link
US (1) US6034059A (es)
EP (1) EP0546007B2 (es)
JP (1) JP2521867B2 (es)
AT (1) ATE147988T1 (es)
AU (1) AU650050B2 (es)
CA (1) CA2088674A1 (es)
DE (1) DE69124382T3 (es)
DK (1) DK0546007T3 (es)
ES (1) ES2097816T5 (es)
GR (1) GR3022935T3 (es)
IE (1) IE912615A1 (es)
PT (1) PT98764B (es)
SE (1) SE9002731D0 (es)
WO (1) WO1992003154A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
AU3956002A (en) 2000-11-28 2002-06-11 Childrens Medical Center Determination of risk and treatment of complications of prematurity
JP3896879B2 (ja) * 2002-03-22 2007-03-22 日本電気株式会社 トラヒック監視システム
ES2532089T3 (es) * 2005-06-02 2015-03-24 Ipsen Biopharmaceuticals, Inc. GH e IGF-1 para el tratamiento de trastornos del crecimiento

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE81779T1 (de) * 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
EP0288478B1 (en) * 1986-01-09 1992-08-19 Brigham And Women's Hospital Use of growth hormone for nitrogen retention under hypocaloric conditions
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
ATE116335T1 (de) * 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).

Also Published As

Publication number Publication date
EP0546007B2 (en) 2003-01-29
IE912615A1 (en) 1992-02-26
JPH05509323A (ja) 1993-12-22
DE69124382T3 (de) 2003-09-11
DE69124382D1 (de) 1997-03-06
US6034059A (en) 2000-03-07
EP0546007B1 (en) 1997-01-22
PT98764A (pt) 1993-09-30
ES2097816T5 (es) 2003-07-16
CA2088674A1 (en) 1992-02-25
WO1992003154A1 (en) 1992-03-05
EP0546007A1 (en) 1993-06-16
ATE147988T1 (de) 1997-02-15
AU8448891A (en) 1992-03-17
DK0546007T3 (da) 1997-03-17
DE69124382T2 (de) 1997-06-26
JP2521867B2 (ja) 1996-08-07
GR3022935T3 (en) 1997-06-30
PT98764B (pt) 1999-01-29
SE9002731D0 (sv) 1990-08-24
AU650050B2 (en) 1994-06-09

Similar Documents

Publication Publication Date Title
DE69327585D1 (de) Befruchtete muscheleier enthaltende zusammensetzung
ATE168560T1 (de) Topische mittel zur transdermalen verabreichung von prodrugderivaten des morphins
GR3034162T3 (en) Liposome-encapsulated taxol, its preparation and its use
ATE126972T1 (de) Formulierung zur behandlung von silage.
ATE185548T1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
DE69217668D1 (de) Vorrichtung zum kultivieren von pflanzen
DE59410052D1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
DE69332713D1 (de) Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen
CO4290359A1 (es) Metodo para tratar la alopecia androgenica con inhibidores 5-alfa-reductasa
DE3583887D1 (de) Ausruestung fuer die behandlung der osteoporose.
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
IL122894A0 (en) Fungicidal mixtures
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
ES2097816T3 (es) Producto y su uso para el tratamiento de estados catabolicos que comprende ifg-1 autentico y cantidades hipocaloricas de nutrientes.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
TW261532B (es)
GB9410639D0 (en) Method of improving fertilization
ATE64300T1 (de) Wirkstoffe zur anwendung bei der behandlung von tumoren.
ES2110258T3 (es) Derivados de 1,3,5(10)-estratrieno activos por via oral.
HUT66153A (en) Pharmaceutical compositions which can be used for preventing and treating of chemotherapy-induced alopecia
ATE128871T1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
DE69427116D1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
ZA919021B (en) Anthelmintic treatment and compositions
MX9203205A (es) Novedosos acidos dimetilamino-hidroxi-alcan-difosfonicos y sales de los mismos, en procedimiento de produccion y composiciones farmaceuticas relacionadas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 546007

Country of ref document: ES